Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?

Bibliography

• WOLFE RA, ASHBY VB, MILFORD EL et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl. J. Med. (1999) 341(23):1725–1730.
   PubMed Web of Science ®Google Scholar
• LECHLER RI, SYKES M, THOMSON AW, TURKA LA: Organ transplantation-how much of the promise has been realized? Nat. Med. (2005) 11(6):605–613.
   Web of Science ®Google Scholar
• MATAS AJ, GILLINGHAM KJ, PAYNE WD, NAJARIAN JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation (1994) 57(61:857–859.
   PubMedGoogle Scholar
• NANKIVELL BJ, BORROWS RJ, FUNG CL, O'CONNELL PJ, ALLEN RD, CHAPMAN JR: The natural history of chronic allograft nephropathy. N Engl. J. Med. (2003) 349(24):2326–2333.
   PubMedGoogle Scholar
• DAVIDSON J, -WILKINSON A, DANTAL J et al.: New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 75(10 Suppl.):553–524.
   Google Scholar
• HOLT DW: Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr. Opin. Nephrol. Hypertens. (2002) 11(6):657–663.
   PubMed Web of Science ®Google Scholar
• UNDRE NA, VAN HOOF J, CHRISTIAANS M et al.: Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc. (1999) 31:296–298.
   PubMed Web of Science ®Google Scholar
• MAHALATI K, BELITSKY P, SKETRIS I,WEST K, PANEK R: Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation (1999) 68(1):55–62.
   PubMed Web of Science ®Google Scholar
• KUEHL P, ZHANG J, LIN Y et ed.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genetics (2001) 27:383–391.
   Google Scholar
• ••The definitive description of thecytochrome P450 single nucleotide polymorphisms.
   Google Scholar
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 61(7):1029–1037.
   Google Scholar
• EVANS WE: Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics (2002) 12(6):421–423.
   PubMedGoogle Scholar
• RENDIC S, DI CF: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. (1997) 29(1-2):413–580.
   PubMed Web of Science ®Google Scholar
• KAMDEM LK, STREIT F, ZANGER UM et al.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. (2005) 51(8):1374–1381.
   PubMed Web of Science ®Google Scholar
• LAMBA JK, UN YS, THUMMEL K et aL: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 12(2):121–132.
   PubMedGoogle Scholar
• MACPHEE TAM, FREDERICKS S, HOLT DW: Pharmacogenetics as a tool to enable the individualisation of immunosuppressive drug treatment for organ transplantation. Minerva Biotecnologica (2004) 16:161–172.
   Web of Science ®Google Scholar
• HUSTERT E, HABERL M, BURK O et aL: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 11:773–779.
   PubMedGoogle Scholar
• HESSELINK DA, VAN SCHAIK RH, VAN DER HEIDEN IP et aL: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. (2003) 74(3):245–254.
   PubMed Web of Science ®Google Scholar
• MACPHEE IAM, FREDERICKS S, TAI T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation (2002) 74(11):1486–1489.
   PubMed Web of Science ®Google Scholar
• MACPHEE IA, FREDERICKS S, TAI T et aL: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. (2004) 4(6):914–919.
   PubMed Web of Science ®Google Scholar
• MACPHEE IA, FREDERICKS S, MOHAMED M et al.: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation (2005) 79(4):499–502.
   PubMed Web of Science ®Google Scholar
• ••The largest published study of theimpact of the CYP3A5 genotype on immunosuppressive drug pharmacology.
   Google Scholar
• THERVET E, ANGLICHEAU D, KING B et aL: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 76(8):1233–1235.
   PubMed Web of Science ®Google Scholar
• ZHENG HX, WEBBER S, ZEEVI A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. (2003) 3(477–483.
   PubMed Web of Science ®Google Scholar
• HAUFROID V, MOURAD M, VAN KERCKHOVE V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14(3):147–154.
   Google Scholar
• TSUCHIYA N, SATOH S, TADA H et aL: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transp/antation (2004) 78(8):1182–1187.
   PubMed Web of Science ®Google Scholar
• ZHENG H, ZEEVI A, SCHUETZ E et aL: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. (2004) 44(2):135–140.
   PubMed Web of Science ®Google Scholar
• ZHAO Y, SONG M, GUAN D et aL: Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant. Proc. (2005) 37(1):178–181.
   PubMed Web of Science ®Google Scholar
• ZHANG X, LIU ZH, ZHENG JM et al.: Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant. (2005) 19(5):638–643.
   PubMed Web of Science ®Google Scholar
• MAT I, PERLOFF ES, BAUER S et al.: MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Clin. Pharmacol. (2004) 58(5):548–553.
   PubMed Web of Science ®Google Scholar
• MIN DI, ELLINGROD VL: Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2003) 25(3):305–309.
   PubMed Web of Science ®Google Scholar
• MIN DI, ELLINGROD VI,, MARSH S, MCLEOD H: CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2004) 26(5):524–528.
   PubMed Web of Science ®Google Scholar
• HESSELINK DA, VAN GELDER T, VAN SCHAIK RH et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. (2004) 76(6):545–556.
   Google Scholar
• ANGLICHEAU D, LE CORRE D, LECHATON S et al.: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. (2005) 5(3):595–603.
   PubMed Web of Science ®Google Scholar
• CATTANEO D, MERLINI S, PELLEGRINO M et al.: Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am. J. Transplant. (2004) 4(8):1345–1351.
   PubMed Web of Science ®Google Scholar
• MARQUET P, DJEBLI N, TOUPANCE O, HOIZEY G, ROUSSEAU A, LE MEUR Y: Sirolimus oral clearance is significantly higher in CYP3A5*1 versus CYP3A5*3 de novo renal transplant recipients with no associated calcineurin inhibitor. Am. J. Transplantation (2005) 5\(Supp1.11):448.
   Google Scholar
• NAKAMOTO T, HASE I, IMAOKA S et al.: Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics (2000) 10:571–575.
   PubMedGoogle Scholar
• SAEKI T, UEDA K, TANAGAWARA Y, HORT R, KOMANO T: Human P-glycoprotein transports cyclosporin A and FK505. J. Biol. Chem. (1993) 268(9):6077–6080.
   PubMed Web of Science ®Google Scholar
• MILLER DS, FRICKER G, DREWE J: p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J. PharmacoL Exp. Ther. (1997) 282(1):440–444.
   PubMed Web of Science ®Google Scholar
• MARZOLINI C, PAUS E, BUCLIN T, KIM RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75(1):13–33.
   PubMed Web of Science ®Google Scholar
• •A very clear account of the MDR-1 single nucleotide polymorphisms.
   Google Scholar
• KIM RB: MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics (2002) 12:425–427.
   PubMedGoogle Scholar
• FROMM MF: Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology (2002) 181–182:299–303.
   Google Scholar
• HOFFMEYER S, BURK O, VON RICHTER O et aL: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. NatL Acad. Sci. USA (2000) 97(7):3473–3478.
   PubMed Web of Science ®Google Scholar
• FELLAY J, MARZOLINA C, MEADEN ER et al.: Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359:30–36.
   PubMed Web of Science ®Google Scholar
• DRESCHER S, SCHAEFFELER E, HITZL M et al.: MDR1 gene polmorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharm. (2002) 53:526–534.
   PubMed Web of Science ®Google Scholar
• SAKAEDA T, NAKAMURA T, HORINOUCHI M et aL: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. (2001) 18(10):1400–1404.
   PubMed Web of Science ®Google Scholar
• KIM RB, LEAKE BF, CHOO EF et aL: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharm. Ther. (2001) 70:189–199.
   PubMed Web of Science ®Google Scholar
• YATES CR, ZHANG W, SONG P et aL: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. Clin. Pharm. (2003) 43:555–564.
   Google Scholar
• CHOWBAY B, CUMARASWAMY S, CHEUNG YB, ZHOU Q, LEE EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics (2003) 13:89–95.
   PubMedGoogle Scholar
• GOTO M, MASUDA S, SAITO H et aL:C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 12:451–457.
   PubMedGoogle Scholar
• •Addresses the genetic contribution of the donor liver.
   Google Scholar
• HASHIDA T, MASUDA S, UEMOTO S, SAITO H, TANAKA K, INUI K: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. PharmacoL Ther. (2001) 69:308–316.
   PubMed Web of Science ®Google Scholar
• ANGLICHEAU D, THERVET E, ETIENNE I et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. PharmacoL Ther. (2004) 75(5):422–433.
   PubMed Web of Science ®Google Scholar
• BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F et al.: MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation (2004) 78(1):21–25.
   PubMed Web of Science ®Google Scholar
• MM I, STORMER E, GOLDAMMER M et al.: MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J. Clin. PharmacoL (2003) 43(10):1101–1107.
   PubMed Web of Science ®Google Scholar
• KUZUYA T, KOBAYASHI T, MORIYAMA N et al.: Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation (2003) 76(5):865–868.
   PubMed Web of Science ®Google Scholar
• FARRELL RJ, MURPHY A. LONG A et al.: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology (2000) 118:279–288.
   Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, DIAZ-BORJON A et al.: Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine (2000) 67(1):30–39.
   Google Scholar
• SINGH D, ALEXANDER J, OWEN A et al.: Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation (2004) 77(4):557–561.
   PubMed Web of Science ®Google Scholar
• DELANEY MP, SMYTHE E, HIGGINS RM, MORRIS AG: Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: role of P-glycoprotein-170. TranspL Int. (2000) 13(4):276–284.
   PubMed Web of Science ®Google Scholar
• MELK A, DANIEL V WEIMER R et al.: P-glycoprotein expression is not a useful predictor of acute or chronic kidney graft rejection. TranspL Int. (1999) 12(1):10–17.
   Google Scholar
• ZHENG HX, WEBBER S, ZEEVI A et al.: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant recipients. Human ImmunoL (2002) 63:765–770.
   PubMed Web of Science ®Google Scholar
• OJO AO, HELD PJ, PORT FK et al.: Chronic renal failure after transplantation of a nonrenal organ. N EngL J. Med. (2003) 349(10):931–940.
   PubMed Web of Science ®Google Scholar
• SIEGSMUND M, BRINKMANN U, SCHAFFELER E et al.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. NephroL (2002) 13(7):1847–1854.
   PubMed Web of Science ®Google Scholar
• KURATA Y, IEIRI I, KIMURA M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. PharmacoL Ther. (2002) 72(2):209–219.
   PubMed Web of Science ®Google Scholar
• HAUSER IA, SCHAEFFELER E, GAUER S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. NephroL (2005) 16(5):1501–1511.
   PubMed Web of Science ®Google Scholar
• •This paper emphasises the importance of considering the genotype of the donor, as well as the recipient, when considering toxicity.
   Google Scholar
• HEBERT MF, DOWLING AL, GIERWATOWSKI G et al.: Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics (2003) 13(11):661–674.
   PubMedGoogle Scholar
• MEIJER OC, DE LANGE ECM, BREIMER DD, DE BOER AG, WORKEL JO, DE KLOET ER: Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdrlA P-glycoprotein knockout mice. Endocrinology (1998) 139(01789–1793.
   PubMed Web of Science ®Google Scholar
• SCHINKEL AH, WAGENAAR E, VAN DEEMTER L, MOL CAAM, BORST P: Absence of the MDRla P-glycoprotein in mice affects tissue distribution ans pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. (1995) 96:1698–1705.
   PubMed Web of Science ®Google Scholar
• YOKOGAWA K, TAKAHASHI M, TAMAI I et aL: P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrl a knockout mice. Pharm. Res. (1999) 16(8):1213–1218.
   PubMed Web of Science ®Google Scholar
• SIDDIQUI A, KERB R, WEALE ME et aL: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N EngL J. Med. (2003) 348:1442–1448.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI A, IEIRI I, KATAOKA Y et aL: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation (2002) 74(4):571–578.
   PubMed Web of Science ®Google Scholar
• ASANO T, TAKAHASHI KA, FUJIOKA M et al.: ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics (2003) 13(11):675–682.
   PubMedGoogle Scholar
• TWENTYMAN PR: Cyclosporins as drug resistance modifiers. Biochem. PharmacoL (1992) 43(1):109–117.
   PubMed Web of Science ®Google Scholar
• ARCECI RJ, STIEGLITZ K, BIERER BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood (1992) 80(6):1528–1536.
   PubMed Web of Science ®Google Scholar
• JETTE L, BEAULIEU E, LECLERC J-M, BELIVEAU R: Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and in other tissues. Am. J. PhysioL (1996) 270:F756–F765.
   Google Scholar
• HAUSER IA, KOZIOLEK M, HOPFER U, THEVENOD F: Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. (1998) 54:1139–1149.
   PubMed Web of Science ®Google Scholar
• LAPLANTE A, DEMEULE M, MURPHY GF, BELIVEAU R: Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-GP. Transplant. Proc. (2002) 34:3393–3395.
   PubMed Web of Science ®Google Scholar
• LOWN KS, MAYO RR, LEICHTMAN AB et al.: Role of intestinal P-glycoprotein (MDR1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. PharmacoL Ther. (1997) 62(3):248–260.
   PubMed Web of Science ®Google Scholar
• BURK O, KOCH I, RAUCY J et aL: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). Biol. Chem. (2004) 279(37):38379–38385.
   Web of Science ®Google Scholar
• HUSTERT E, ZIBAT A, PRESECAN-SIEDEL E et al.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. (2001) 29(11):1454–1459.
   PubMed Web of Science ®Google Scholar
• HUANG YH, GALIJATOVIC A, NGUYEN N et al.: Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics (2002) 12(4):287–297.
   PubMedGoogle Scholar
• HESSELINK DA, VAN HEST RM, MATHOT RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. (2005) 5(5):987–994.
   PubMed Web of Science ®Google Scholar
• ITO S, IEIRI I, TANABE M, SUZUKI A. HIGUCHI S, OTSUBO K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics (2001) 11(2):175–184.
   PubMedGoogle Scholar
• HASHIMOTO K, UCHIUMI T, KONNO T et al.: Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology (2002) 36(5):1236–1245.
   PubMed Web of Science ®Google Scholar
• BAMBERGER CM, BAMBERGER AM, DE CASTRO M, CHROUSOS GP: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest (1995) 95(6):2435–2441.
   PubMed Web of Science ®Google Scholar
• LEUNG DY, HAMID Q, VOTTERO A et aL: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J. Exp. Med. (1997) 186(9):1567–1574.
   PubMed Web of Science ®Google Scholar
• HONDA M, ORII F, AYABE T et aL: Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology (2000) 118(5):859–866.
   PubMed Web of Science ®Google Scholar
• KUNZ S, SANDOVAL R, CARLSSON P, CARLSTEDT-DUKE J, BLOOM JW, MIESFELD RL: Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. MoL EndocrinoL (2003) 17(12):2566–2582.
   PubMedGoogle Scholar
• GLANDER P, HAMBACH P, BRAUN KP et aL: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4(12):2045–2051.
   PubMed Web of Science ®Google Scholar
• FUTER O, SINTCHAK MD, CARON PR et aL: A mutational analysis of the active site of human Type II inosine 5'-monophosphate dehydrogenase. Biochim. Biophys. Acta (2002) 1594(1):27–39.
   PubMedGoogle Scholar
• BOWNE SJ, SULLIVAN LS, BLANTON SH et aL: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. MoL Genet. (2002) 11(5):559–568.
   PubMed Web of Science ®Google Scholar
• CARDENAS ME, UM E, HEITMAN J: Mutations that perturb cyclophilin A ligand binding pocket confer cydosporin A resistance in Saccharomyces cerevisiae. BioL Chem. (1995) 270(30:20997–21002.
   Google Scholar
• FRUMAN DA, WOOD MA, GJERTSON CK, KATZ HR., BURAKOFF SJ, BIERER BE: FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur. j ImmunoL (1995) 25(2):563–571.
   PubMed Web of Science ®Google Scholar
• AOYAMA T, YAMANO S, WAXMAN DJ et al.: Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. (1989) 264(1010388–10395.
   Google Scholar
• JOHNSTON A, CHUSNEY G, SCHUTZ E, OELLERICH M, LEE TD, HOLT DW: Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther. Drug Monit. (2003) 25(2):167–173.
   PubMed Web of Science ®Google Scholar
• WRIGHTON SA, BRIAN WR, SARI MA et al.: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). MoL PharmacoL (1990) 38(2):207–213.
   PubMed Web of Science ®Google Scholar
• LINDHOLM A, WELSH M, ALTON C, KAHAN BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. PharmacoL Ther. (1992) 52:359–371.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN JJ, KAHAN BD: Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J. Clin. PharmacoL (1997) 37(5):405–415.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, KAPLAN B, SILVA HT et al.: Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am. J. Transplant. (2003) 3(5):606–613.
   PubMed Web of Science ®Google Scholar
• TORNATORE KM, BIOCEVICH DM, REED K, TOUSLEY K, SINGH JP, VENUTO RC: Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation (1995) 59(5):729–736.
   PubMed Web of Science ®Google Scholar
• SHIMADA T, TERADA A, YOKOGAWA K et aL: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation (2002) 74(10):1419–1424.
   PubMed Web of Science ®Google Scholar
• DOWLING TC, BRIGLIA AE, FINK JC et al.: Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin. PharmacoL Ther. (2003) 73(5):427–434.
   PubMed Web of Science ®Google Scholar
• MICHAUD J, DUBE P, NAUD J et aL: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. PharmacoL (2005) 144(8):1067–1077.
   PubMed Web of Science ®Google Scholar
• ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. NephroL (2003) 14:1889–1896.
   PubMed Web of Science ®Google Scholar
• VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. (2001) 47(6):1048–1052.
   PubMed Web of Science ®Google Scholar
• RIVORY LP, QIN H, CLARKE SJ et al.: Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur. J. Clin. PharmacoL (2000) 56:395–398.
   PubMed Web of Science ®Google Scholar
• MIN DI, ELLINGROD VL: C3435T mutation in exon 26 of the human MDR1 gene ans cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2002) 24:400–404.
   PubMed Web of Science ®Google Scholar